Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move (TSX:
$WEED.TO) (NYSE: $CGC) (OTCQB: $SING) (OTC: $ORGH) (OTCQB: $AXIM) (TSXV: $AVCN.V)
(TSXV: $PCLO.V) (OTC: $PHCEF)
Delta, Kelowna BC –August 8,
2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source
covering leading sectors including marijuana and hemp stocks and its potcast
site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insight from thought leaders and
experts.
Listen to the
podcast:
Read this in full
at https://www.investorideas.com/news/2019/cannabis-potcasts/08081WEED-CGC-SING-ORGH-AXIM-AVCN-PCLO-PHCEF.asp
Today's podcast overview/transcript:
Good afternoon and welcome to another episode of
Investorideas.com "Potcast" featuring cannabis news, stocks to watch
as well as insights from thought leaders and experts.
In
today’s podcast we look at a few early announcements.
Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) announced that it has partnered with one of the
largest global sellers of premium cannabis accessories, Greenlane Holdings, Inc, (NASDAQ: GNLN) that gives Greenlane exclusive
distribution rights of Storz & Bickel vaporizers throughout the United
States.
Storz
& Bickel, a subsidiary of Canopy Growth based in Tuttlingen, Germany, has a
22-year history as the global leader in vaporizer design. The company has won
accolades for developing an automated and internationally certified factory,
achieving ISO 13845 certification in 2009 and exporting to over 50 markets
around the world. Storz & Bickel first introduced the world-renowned
Volcano® product line in 2000 and since then has worked tirelessly to continue
innovating and perfecting the industry's leading tabletop vaporizer, in
addition to their successful portable handhelds including the Crafty® and
Mighty® devices.
Greenlane
has been Storz & Bickel's exclusive U.S. distribution partner since January
2018 and the new agreement signed with Canopy Growth will allow for robust
growth in the American market along with continued distribution to the Canadian
market. Greenlane boasts an extensive distribution network within North America
which includes over 11,000 retail locations spanning smoke and vape shops and
licensed cannabis dispensaries. Through their distribution channels, Greenlane
will bring Storz & Bickel's newest desktop vaporizer technology—the Volcano
Hybrid—to market. The Hybrid model offers improved airflow management, faster
heat-up times, easy to use touch display, a rotatable tube system for an
alternate inhalation method and increased safety and functionality through
Bluetooth app control.
"Establishing and extending this
exclusive partnership with Greenlane has played an important role in cementing
Storz & Bickel's brand reputation for quality, safety and performance in the United States." commented Peter Popplewell, PhD., Canopy Growth Chief
Technology Officer. "We have seen tremendous success with their smaller
handheld devices, including the Mighty, and we are excited to introduce Storz
& Bickel's latest update on the Volcano as consumers continue to be drawn
towards top-quality vaporizer technology."
SinglePoint (OTCQB:
SING) announced
today that it has signed a master distribution
agreement with Pure Products LLC to become the primary sales and marketing
solution for the company’s line of “Pure Hemp” cigarettes.
This distribution agreement is a natural
fit for SinglePoint CEO Greg Lambrecht as previously he led Premium Cigars
International to an IPO NASDAQ listing. The company distributed and serviced
over 30,000 accounts throughout North America. “We are excited for this
opportunity. I have many contacts still in the business from my prior
distribution company and look forward to bringing Pures’ hemp cigarettes to
market. There is a massive opportunity and we have been seeing retailers
looking for this type of product during our due diligence into the space,”
states Greg Lambrecht CEO SinglePoint.
According to Steve Ross, President of
Pure Products LLC, "A phenomenon is occurring where people are
substituting or modifying tobacco consumption with low THC cannabis/hemp
cigarettes containing less than .3% THC. We believe we have the best
all-natural hemp cigarette in the market and are tremendously excited to
partner with Singlepoint to accelerate our product placement into retail
outlets nationwide.”
Singlepoint President Wil Ralston stated,
“Our team is excited to represent this outstanding product and we are confident
that we can help establish “Pure” as a meaningful leader in the natural hemp
cigarette category. We believe retail outlets and specialty shops across the
country are anxious to dedicate shelf space to CBD, especially hemp cigarettes.
The Pure brand brings an elevated standard of product to the market, enhancing
the consumer’s experience while adding revenues and profits to these
retailers.”
Ralston added, “Not long ago, SinglePoint
made a significant commitment to be a major provider in the industrial hemp
space and the agreement with Pure Products is another bold move for the company
to solidify our place in the industry.
Teaming with Steve Ross and the Pure Products team accelerates our plan
to put finished goods into retail stores.”
OrgHarvest,
Inc. (OTC:
ORGH) announced a
license agreement has been entered into by and between OrgHarvest Inc. and
Keith DeSanto of Rhamnolipid, Inc. in
which Rhamnolipid has invented and filed numerous pest and disease control
agricultural application patents for rhamnolipid products in the cannabis and
hemp industries. Hemp and cannabis rhamnolipid applications include specific
blends, peptides, rhamnolipid liposomes, injection technology and pest
repellants.
“The cannabis and hemp industries have
been plagued by various diseases, pests and fungi in the cultivation process.
We are excited to announce that Mr. DeSanto will be joining the OrgHarvest team
as our vice president of technology, bringing with him this game-changing rhamnolipid technology. This will mean fewer
crop failures and preventable losses to our bottom line,” said Frank Celecia,
CEO of OrgHarvest.
OrgHarvest seeks to launch cannabis cultivation
and production operations in Las Vegas, Nevada, employing a high-tech,
100,000-square-foot glass greenhouse imported from the Netherlands that has the
capacity to produce 450 pounds of cannabis flower per week, enabling the
Company to potentially quadruple revenues after its second year of operation.
Carlos Calixto, COO of OrgHarvest, was
very pleased to see the test results of these patent-pending rhamnolipid
applications. The Company is focused on
the acquisition of and/or joint venturing with cannabis dispensaries as well as
the production and distribution of cannabis flower with high THC values and
oils used in manufacturing edibles, beverages and pharmaceuticals. The Company
expects to find a tremendous market in the sale of rhamnolipids to the hemp
industry.
OrgHarvest’s competitive advantages
include risk diversification through the approach of growing cannabis using a
high-tech custom Dutch glasshouse manufactured in the Netherlands, which offers
a unique combination of advantages unmatched by OrgHarvest’s competitors.
Compared to other cannabis operations, the Company differentiates itself by
offering a facility that can provide higher-quality and pest-free flowers and a
stronger focus on developing strains and new products using exclusive patented
technology.
AXIM® Biotechnologies, Inc. (OTCQB:
AXIM), a world leader in cannabinoid research
and development, today
announced that the United States Patent and
Trademark Office (USPTO) has issued a Notice of Allowance for a patent
(Application No. 16/293,136) on anti-microbial compositions comprising
cannabinoids, specifically CBG. The USPTO granted this patent allowance from
AXIM’s patent application filed on March 5, 2019.
All products that AXIM has the
opportunity to produce under this patent will be made using CBG, a strong
anti-microbial agent. AXIM aims to utilize this patent in the development of
products for the treatment of symptoms associated with fungal-related diseases,
including tinea pedis, commonly known as athlete’s foot. AXIM intends to
develop future products under this patent in an aerosol form and foot powder
for easy application. Other products with different anti-microbial applications
are also considered for development under this patent.
According to Grand View Research, the
global antifungal drugs market is expected to reach $12.7 billion by 2025, giving AXIM the opportunity
to offer its unique products to a large market.
“We have recognized the importance of
patents since our early days with our well-known patent on chewing gum as a
delivery mechanism for all cannabinoids,” said John W. Huemoeller II, Chief
Executive Officer of AXIM® Biotech. “We look forward to continuing to lead
cannabis innovation with this patent and future patents as the industry
advances in both market growth and legitimacy.”
Once granted this patent, AXIM will hold
eight issued patents and 11 pending patent applications.
Avicanna
Inc. (TSX:
AVCN) a biopharmaceutical company focused on
the development, manufacturing and commercialization of plant-derived
cannabinoid-based products, announced that
it has entered into an agreement with
Sigma Analytical Services Inc. to establish a joint venture for the testing
of cannabis and cannabis-based products in Colombia.
The joint venture will leverage Sigma
Analytical's expertise, methodology, and intellectual property in cannabis and
derived product testing to establish a laboratory to test cannabis genetics and
products. Independent analytical services will be managed and operated by an
operating company with complete adherence to techniques and procedures
developed and implemented by Sigma Analytical. The laboratory is expected to be
located within the SMGH facilities and testing services will be provided to
Santa Marta Golden Hemp S.A.S. ("SMGH")
and Sativa Nativa S.A.S. ("Sativa
Nativa"), two subsidiaries of Avicanna, and are expected to also be
offered to a variety of large licensed producers to small scale partner
farmers. The parties anticipate that the laboratory will be the first
cannabinoids-only, analytical laboratory and independent testing service in
South America to meet Health Canada, European Pharmacopeia, US Pharmacopeia,
and compliant to EU GMP standards. With technical transfer currently underway,
the completion and launch of the laboratory services is expected to occur early
in the fourth quarter of 2019.
The laboratory will provide a
comprehensive suite of cannabis specific testing, which will include
pesticides, heavy metals, residual solvents, aflatoxins, microbial, genotyping,
and cannabinoid and terpene profiling.
Current and proposed legislation requires
independent laboratory testing for cannabis extract for future medical sales
and export. However, as full-suite testing in line with global standards is
currently unavailable in Colombia, it requires many companies to go through the
lengthy process to export samples for validated testing results.
PharmaCielo
Ltd. (TSXV:PCLO) (OTC:PHCEF), the
Canadian parent of Colombia's premier cultivator and producer of
medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today
announced it has joined the TruTrace Technologies, Inc. (CSE:TTT) (OTCQB:TTTSF) and
Shoppers Drug Mart initiated medical cannabis pilot verification program.
PharmaCielo is the first international medical cannabis producer to join this
seed-to-sale tracking initiative.
"We are pleased to have a recognized
international medical cannabis producer joining and supporting our technology
and the Canadian Pilot Program. As a new and burgeoning industry that impacts
people's health and wellbeing, it is imperative to build accountability into
the supply chain and product offerings. I am thrilled to have partners like
PharmaCielo joining the platform with Shoppers, sharing the same vision that we
have and representing the global industry perspective to push it forward,"
said TruTrace Technologies CEO Robert Galarza.
"The product registration hub is the
right type of initiative the industry needs to bring it on par with the
pharmaceutical and food industries in terms of full transparency and
traceability," said David Attard, CEO with PharmaCielo Ltd. "We see
great value in this technology and its importance to the industry. PharmaCielo
fully supports this initiative, as it aligns with our commitment to adhering to
the highest operational and ethical standards in everything we do."
Investor ideas reminds all listeners to read our disclaimers and
disclosures on the
Investorideas.com website and this podcast is not an endorsement
to buy products or services or securities. Investors are reminded all
investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also
available on iTunes, Spotify, Google
Play Music, Stitcher, Spreaker, YouTube
via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark
on the blockchain through Cognate, Inc. CM Certification-Registration Number:
10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news
source publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com original
branded content includes the daily Crypto Corner and Podcast, Play
by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI
Eye Podcast and column covering developments in
AI.
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where
permissible by law. Our site does not possess, distribute, or sell cannabis
products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment